CAS: 3824-21-3; 2-Fluoro-4-Iodo-1-Methoxybenzene

该化合物是一种卤化芳香化合物,其中含有2位置的氟原子,4位置的碘替代体和苯环1位置的甲氧基组.这一结构使它在有机合成中具有多种用途的中间体,特别是用于交织反应,如铃木或松冈竹草交配,其中碘合金是一个有效的离子组.用电提取的氟和电饱和甲基氧组有助于其功能化反应中的再活性和选择性.其定义明确的替代模式也有利于合成制药,农用化学和材料科学中的复杂分子.该化合物由于敏感性,通常在惰性条件下处理.

英文名称2-Fluoro-4-Iodo-1-Methoxybenzene
中文名称2-氟-4-碘-1-甲氧基苯
IUPAC名称2-fluoro-4-iodo-1-methoxybenzene
其它别名(3-氟-4-甲氧基苯基)碘化物; Benzene, 2-Fluoro-4-Iodo-1-Methoxy-
CAS编号3824-21-3
MFCD编号:MFCD00691526
分子式:C7H6FIO
分子量:252.03
产品CID: 1393812
产品分类有机原料→分子砌块→芳环类化合物→苯类化合物

相似结构搜索
产品信息参考;
InChIKey: YZAKENGNADHGSS-UHFFFAOYSA-N
InChI=1S/C7H6FIO/c1-10-7-3-2-5(9)4-6(7)8/h2-4H,1H3…
计算化学: 氢键受体数1.0氢键供体数0.0可旋转键数1.0

MSDS等安全信息

GHS符号GHS07
警示词Warning
危险描述H227-H315-H319-H335
防范说明P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501
危险品标志Xi

上下游产品

CAS号366-99-4 3-氟-4-甲氧基苯胺 | CAS号2713-28-2 2-氟-4-碘苯酚 | CAS号935660-93-8 4-Iodo-7-methox...

合成工艺路线路线简述

3-氟-4-甲氧基苯胺置于硫酸,Sodium Nitrite体系中,化学反应生成2-氟-4-碘-1-甲氧基苯
参考文献:Aromatic Fluorine Compounds. Viii. Plant Growth Regulators And Intermediates1,2
标题:Aromatic Fluorine Compounds. Viii. Plant Growth Regulators And Intermediates1,2
摘要:
Doi:10.1021/ja01510A021

海关参考信息

2905110000-甲醇
2908199090-其他酚的卤化衍生物
2908999090-其他酚的硝化衍生物
2918290000-其他含酚基羧酸
💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
详情请参考：📖 海关编码查询和海关进出口税则

专利信息

专利号:WO-2007002173-A1
优先权日:2005-06-22
标题:Hiv-1 protease inhibitors, and methods of making and using them
发明人：RANA TARIQ M; ALI AKBAR; CAO HONG; SAI KIRAN KUMAR REDDY GA; ANJUM SAIMA GHAFOOR
权利人:UNIV MASSACHUSETTS; RANA TARIQ M; ALI AKBAR; CAO HONG; SAI KIRAN KUMAR REDDY GA; ANJUM SAIMA GHAFOOR
摘要:One aspect of the invention relates to the design, synthesis and biological activity of novel HIV-1 protease inhibitors incorporating N-phenyloxazolidine-5-carboxamides into the (hydroxyethylamino)sulfonamide scaffold as P2 ligands. For example, the present invention relates to inhibitors with variations at the P2 phenyloxazolidine and the P2' phenylsulfonamide moieties. Remarkably, compounds with an (S)-enantiomer of substituted phenyloxazolidines at P2 show highly potent inhibitory activities against wild-type HIV-1 protease. In certain embodiments, the inhibitors of the invention have Ki values in low picomolar (pM) range. In certain embodiments, the inhibitors of the invention were shown to be active against a variety of multi-drug resistant (MDR) HIV-1 proteases, each representing different paradigm of drug resistance.